The company welcomes Mark Siegel (Menlo Ventures), Matt Ocko (DCVC), and John Kuelper (Ascension Ventures) to its board of directors.
This investment comes on the heels of Cofactor securing CAP/CLIA accreditation of its platform in order to process clinical-grade formalin-fixed paraffin embedded (FFPE) patient samples, as well as the validation and launch of two initial products: Pinnacle and Paragon.
Pinnacle examines nearly 600 RNA biomarkers known to be associated with response to targeted therapeutics, while Paragon is an RNA-based immunophenotyping assay with broad applications to the field of immuno-oncology and beyond.
While most attention has been paid to applications of DNA analysis for precision medicine, Cofactor's team of past Human Genome Project scientists have spent the last four years optimising its platform specifically for the analysis of RNA, a rich source of information on the molecular mechanisms involved in complex and heterogeneous diseases such as cancer that cannot be uncovered through DNA alone.
Cofactor Genomics uses RNA to help researchers and clinicians understand, diagnose, and predict drug response for the 95% of disease that can't be assessed by DNA alone.
Founded by three former Human Genome Project scientists, Cofactor has built a proprietary platform capable of overcoming the chemical and computational challenges of performing complex RNA fingerprint analysis on clinical-grade human samples.
Cofactor said it has contracts to provide RNA sequencing and analysis services to the research arms of eight of the world's largest pharma and biotech companies, and is in the process of commercializing a suite of clinical diagnostic assays targeting oncologic, immunologic, and neurodegenerative diseases.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
RyboDyn joins Lilly Gateway Labs' innovation hub
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study